Kirsten Ludwig, PhD


Assistant Professor

Biomedical Science

Dr. Kirsten Ludwig has been an educator since 2007, when she began teaching at Chapman University and guest lecturing at the University of Virginia Medical School. In 2012 she joined the faculty of Hawthorn University to help grow the doctoral department of holistic nutrition. Since then, Dr. Ludwig has developed and taught a variety of courses at several institutions, including Brandman University, Mount Saint Mary’s University, and Pasadena City College. Dr. Ludwig is also a walking quadriplegic. In 2021, she was thrown from her horse and paralyzed from the shoulders down. She spent a year learning to walk again, as well as feed and clothe herself. Dr. Ludwig is an active member of the community who serves on committees and workgroups to promote the visibility of all types of disabilities in medical education.

Faculty headshot of Kirsten Ludwig, PhD

Education and Training

BA, University of Virginia
MS, University of Virginia
PhD, University of Virginia
Postdoctoral Scholar, University of California, San Diego
Postdoctoral Fellow, University of California, Los Angeles

Professional Positions

Adjunct Professor
Chapman University
Adjunct Professor
University of Massachusetts Global
Professor, Doctoral Studies
Hawthorn University
Adjunct Professor
College of the Canyons
Adjunct Professor
Pasadena City College
Senior Research Associate III
University of California Los Angeles
Adjunct Professor
Mount Saint Mary’s University
Assistant Professor
Kaiser Permanente Bernard J. Tyson School of Medicine

Honors and Awards

Dean’s List
University of Virginia
Who’s Who Among Students in American Universities and Colleges
University of Virginia
Golden Key International Honour Society
Scholar-In-Training Award
American Association of Cancer Research
2010, 2015
Excellence in Teaching Award
College of the Canyons

Scholarly Activities

Selected peer-reviewed research manuscripts
  • Ludwig K, Tse ES, Wang JY. Colon Cancer Cells Adopt an Invasive Phenotype Without Mesenchymal Transition in 3-D but not 2-D Culture in Response to the Combined Stimulation with EGF and Crypt Growth Factors. BMC Cancer 2013, May 2:13(1):221-25.
  • Ludwig K, Manukyan A, Sanchez-Manchinelly S, Parsons SJ, Stukenberg TP. A complex of p190RhoGAP and anillin modulates RhoGTP and the cytokinetic furrow in humans. Journal of Cell Science. 2015 Jan 1: 128(1): 50-60.
  • Ludwig K, Kornblum HI. Molecular markers in glioma. J. Neurooncol. 2017, Sep;134(3): 505-512.
  • Garrett M, Sperry J, Braas D, Yan W, Le TM, Mottahedeh J, Ludwig K, Eskin A, Qin Y, Levy R, Breunig JJ, Pajonk F, Graeber TG, Radu CG, Christof H, Prins RM, Lai A, Liau LM, Coppola G, Kornblum HI. Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities. Cancer Metabolism. 2018, Apr 17;6:4.
  • Laks DR, Oses-Prieto JA, Alvarado AG, Nakashima J, Chand S, Assam DB, Gholkar AA, Sperry J, Ludwig K, Condro MC, Nazarian S, Cardenas A, Shih MYS, Damoiseaux R, France B, Orozco N, Visnyei K, Crisman TJ, Gao F, Torres JZ, Coppola G, Burlingame AL, Kornblum HI. A molecular cascade modulates MAP1B and confers resistance to mTOR inhibition in human glioblastoma. Neuro Oncology. 2018, May 18;20(6):764-775.
  • Aussem A, Ludwig K. The potential for reducing Lynch Syndrome cancer risk with nutritional Nrf2 activators, Nutrition and Cancer. 2020. Jan; 73(3): 404-419.